EU backs AstraZeneca's drug for prevention of infant RSV

[September 16, 2022]  (Reuters) - AstraZeneca said on Friday its drug for preventing infant RSV, Beyfortus (nirsevimab), was recommended for approval in the European Union by a European Medicines Agency committee.

The drugmaker also said if Beyfortus is approved, it would become the first protective option for newborn and infant population against RSV lower respiratory tract disease.

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid

(Reporting by Amna Karimi in Bengaluru; editing by Uttaresh.V)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.